🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

👇Check this new article from our own Benedetta Conte @prat_aleix and Fara Brasó Maristany 👏👏👏

Very happy to see that our paper on eBioMedicine – The Lancet Discovery Science is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix EVOMET Fara Brasó Maristany

🎯 B-cell/immunoglobulin signature (IGG) was associated with improved EFS (HR = 0.77) and OS (HR = 0.79) across 7 cohorts of early stage TNBC 🕵🏼‍♀️IGG + clinical features could help identifying pts benefitting from intensified or de-intensified tp 👏🏻 🤩Benedetta Conte OncoAlert

Just out 🚨on eBioMedicine – The Lancet Discovery Science Study explores the potential of a B-cell/immunoglobulin signature (IGG), alone or combined with tumor burden, to predict prognosis and treatment response in early-stage triple-negative #BreastCancer ➡️ indicating its promise in guiding personalized

Carmen Criscitiello approaching several controversies in the real world oncology in BRCA/HR+ adjuvant scenario ▪️How to choose between CDKi and PARPi? ▪️ Are CDKi less effective in BRCAmut? ▪️ Can we combine at least sequentially CDKi and PARPi? #ESMOBreast24 #ESMOAmbassadors

Proffered paper session 1 at #ESMOBreast24: first results from #DOLAF trial showing very promising activity in advanced ER+/HER2- #BreastCancer of the combination #olaparib #durvalumab and #fulvestrant particularity in #BRCA carriers ESMO - Eur. Oncology #ESMOambassadors OncoAlert #bcsm

Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussion by Sara Tolaney (Sara Tolaney), recapitulating the current status & future hopes for one of the most challenging presentations of breast cancer. #ESMOBreast24

Patient-level meta-analysis shows HER2DX is associated with survival outcomes in patients with early-stage HER2+ BC presented by Guillermo Villacampa #ESMOBreast24 OncoAlert #bcsm

TDXd can be reintroduced after G1 ILD and pts will gain benefit without any ILD recurrence in most cases. Don’t forget to follow up with CT 👉🏻 33% of pts experiencing ILD will experience it again #ESMOBreast24 Hope Rugo

HER2DX stratify HER2+eBC patients beyond standard clinicopathological factors and beyond pCR! Data from >1500 pts from patient-level meta-analysis! Excellent presentation from rockin’ Guillermo Villacampa! REVEAL GENOMICS @prat_aleix SOLTI #cancerresearch

Super importante conference! Do not miss it!! ⬇️⬇️⬇️⬇️⬇️

#ESMOBreast24 key takeaways MarleenKokLab Wishlist includes #HER2DX and the development of thedefinitivetrial.eu to achieve better outcomes #precisiononcology #breastcancer

At #ASCO24 Matteo Lambertini, MD PhD presents analysis on BRCA BCY Collaboration including young BRCA carriers affected by eBC: ➡️ Different clinical behavior between BRCA1 and 2 carriers ➡️ Early identification of carriers can lead to improvement in prognosis OncoAlert Università di Genova

Great discussion by dr Krop Yale University: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24 OncoAlert

UPO - Università Oncology at #ASCO24 Alessandra Gennari MD PhD Benedetta Conte

I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NCT06446882. First SIV this summer! 🔗Link clinicaltrials.gov/study/NCT06446…

Hi from Vienna! If you are in the city, join us tomorrow at IMP for the "Metastasis mechanisms workshop" with @johannes_zuber Juliane Winkler M. Bentires-Alj and @BMaierLab

Super Fara Brasó Maristany and colleagues!!!!

Che bella sensazione leggere il nome di Filippo Conte come autore di un pezzo su La Stampa !!! lastampa.it/politica/2024/…